Overactive Bladder Treatment Market To Reach USD 5.25 Billion By 2030

Posted by tushar on March 27th, 2025

Overactive Bladder Treatment Market Growth & Trends

The global overactive bladder treatment market size is expected to reach USD 5.25 billion by 2030, and is estimated to register a CAGR of 4.8% over the forecast period, according to a new report by Grand View Research, Inc. Factors such as the growing awareness about the overactive bladder (OAB) condition, along with rising R&D investments to develop novel formulations for this disease, are projected to drive the global market. In addition, rising competition owing to high demand for OAB medications and treatments and rising emphasis of major players to manufacture drugs is another vital factor propelling the demand forward.

Rising awareness about OAB and urinary incontinence among the population is one of the major factors bolstering the growth of the market. Various key players operating in the industry undertake numerous initiatives to raise awareness about the overactive bladder condition. For instance, in January 2023, Urovant Sciences, a key player operating in the market, collaborated with actress and patient Holly Robinson Peete under a campaign to bring awareness to OAB. Such initiatives help increase awareness and knowledge about the treatment options thereby increasing treatment adoption.

Moreover, increasing investments to develop innovative formulations and treatments targeting OAB are anticipated to fuel growth over the forecast period. For instance, in November 2019,  EBT Medical, Inc., a startup, received funding of USD 10 million in series A for developing noninvasive neuromodulation technology to treat overactive bladder. Thus, developments and investments focusing on medications and treatments are anticipated to fuel the geographic expansion.

Furthermore, industry participants are undertaking various strategies like collaborations and new product launches to maintain their position in this competitive market. For instance, in March 2023, KYORIN Pharmaceutical Co., Ltd. collaborated with Sumitomo Pharma Co., Ltd. to develop, manufacture, and commercialize Vibegron for OAB in Taiwan and other Asian Countries like Singapore, Hong Kong, Indonesia, and Vietnam. Such collaborations among major players are expected to increase the accessibility of drugs and treatments across the countries, which can further propel growth in the coming years.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/overactive-bladder-treatment-market-report

Overactive Bladder Treatment Market Report Highlights

• Mirabegron drug dominated the market in 2023 with a which can be attributed to the high adoption and prescription rate of Mirabegron for treating OAB
• Among disease-type segments, the idiopathic overactive bladder segment was the largest revenue contributor for the industry in 2023 due to its high prevalence rate
• In the distribution channel segment, the retail pharmacies dominated the market. The higher revenue growth is attributed to the presence of established retail pharmacies offering OAB drugs and its better patient compatibility
• North America dominated the market for overactive bladder treatment in 2023 owing to the presence of key players such as Pfizer, Inc., AbbVie, Inc., and Viatris, Inc. across the region

Overactive Bladder Treatment Market Segmentation

Grand View Research has segmented the global overactive bladder treatment market based on type, disease type, distribution channel and region:

Overactive Bladder Treatment Type Scope Outlook (Revenue, USD Million, 2018 - 2030)

• Anticholinergics
• Mirabegron
• Botox
• Neuromodulation
• Other

Overactive Bladder Treatment Disease Type Scope Outlook (Revenue, USD Million, 2018 - 2030)

• Idiopathic Overactive Bladder
• Neurogenic Overactive Bladder

Overactive Bladder Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies
• Retail Pharmacies
• Others

Overactive Bladder Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

List of Key Players in the Overactive Bladder Treatment Market

• Pfizer, Inc
• AbbVie Inc.
• Astellas Pharma Inc.
• Medtronic
• Sumitomo Pharma America, Inc.(Urovant Sciences.)
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Hisamitsu Pharmaceutical Co. Inc
• Macleods Pharmaceuticals Ltd.
• Endo International plc

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/overactive-bladder-treatment-market-report